Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. CALC
CALC logo

CALC Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy CalciMedica Inc (CALC) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Sell
Latest Price
0.960
1 Day change
-3.24%
52 Week Range
7.200
Analysis Updated At
2026/07/03
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

CALC is not a good buy right now for a beginner long-term investor with $50,000-$100,000. The stock lacks strong proprietary buy signals, has weak near-term trend expectations, and the latest price action is negative. The only supportive points are a recent insider buy and relatively constructive options call positioning, but these are not enough to offset the weak technical setup and lack of clear fundamental confirmation.

Technical Analysis

The technical picture is mixed to weak. CALC closed at 0.9389 after a -7.17% regular-session drop, which is a bearish short-term move. MACD histogram is slightly positive at 0.0166 but is contracting, suggesting momentum is fading rather than strengthening. RSI_6 at 59.8 is neutral, so the stock is not oversold and does not offer an obvious rebound setup. Moving averages are converging, which usually signals indecision rather than a strong uptrend. Key levels show resistance at 1.076 and 1.22, with support at 0.843 and 0.61. The stock trend estimate also points to weakness, with a 60% chance of -0.67% next day, -4.3% next week, and -4.23% next month.

Options Data

Bullish
Open Interest Put-Call Ratio
Neutral
Option Volume Put-Call Ratio

Options sentiment is mildly bullish on paper because put-call ratios are at 0.0 for open interest and 1.0 for volume, but the absolute activity is very small (today's volume 2, open interest 2863, call open interest 2855 vs put open interest 8). Implied volatility is very high at 240.5, historical volatility is 172.33, and the IV rank is only 17.21, meaning option pricing remains elevated but not at an extreme relative percentile. This looks more like a thinly traded speculative name than a conviction options setup.

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
4
Buy
7

Positive Catalysts

  • The option flow is not bearish, with put-call ratios showing call-side dominance. MACD remains slightly above zero, which leaves room for a near-term technical bounce if buying interest returns.

Neutral/Negative Catalysts

  • The stock fell sharply in the regular session and remains under pressure. There are no AI Stock Picker or SwingMax signals today, so there is no proprietary buy signal to support entry. Hedge funds and insiders are neutral overall aside from the single insider purchase. The model-based trend forecast is negative over the next day, week, and month. No congress trading support is present, and no major news catalyst for CALC itself was provided beyond the insider purchase.

Financial Performance

No usable latest-quarter financial snapshot was available due to a data error, so there is no confirmed quarterly revenue or earnings growth trend to support a long-term buy decision. Because the latest quarter season is not provided, the fundamental growth picture cannot be validated from the supplied data.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target trend data was provided, so Wall Street sentiment cannot be confirmed. Based on the available information, the pros view would likely focus on insider buying and speculative upside from a low share price, while the cons view is stronger: weak price action, no proprietary buy signal, thin options activity, and no clear fundamental support.

Wall Street analysts forecast CALC stock price to rise
1 Analyst Rating
Wall Street analysts forecast CALC stock price to rise
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.988
sliders
Low
20
Averages
20
High
20
Current: 0.988
sliders
Low
20
Averages
20
High
20
Oppenheimer
Oppenheimer
Outperform
downgrade
$20 -> $10
AI Analysis
2026-03-05
Reason
Oppenheimer
Oppenheimer
Price Target
$20 -> $10
AI Analysis
2026-03-05
downgrade
Outperform
Reason
Oppenheimer lowered the firm's price target on CalciMedica to $10 from $20 and keeps an Outperform rating on the shares. The firm notes CalciMedica reported updates to its programs in acute kidney injury and acute pancreatitis along with quarterly financials. The most important development is the absence of any drug-related toxicity following thorough internal/external review of the unblinded Phase 2 KOURAGE dataset - as CalciMedica had indicated after voluntarily discontinuing the trial in late January.
H.C. Wainwright
H.C. Wainwright
Buy -> Neutral
downgrade
2026-01-29
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
2026-01-29
downgrade
Buy -> Neutral
Reason
H.C. Wainwright downgraded CalciMedica to Neutral from Buy without a price target. The immediate discontinuation for the Phase 2 KOURAGE clinical trial in acute kidney injury removes a major catalyst for the shares, the analyst tells investors in a research note. The firm looks to upcoming safety and population clarity as the company reviews the unblinded dataset to determine a potential path forward.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for CALC
Unlock Now

People Also Watch